I am pleased to announce that Dr. Charles Bennett has been able to successfully publish a paper titled “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.” The paper was officially accepted by The Journal of Community and Supportive Oncology for February 2016. (Link below)
New serious Fluoroquinolone (FQ) associated safety concerns have been identified through novel collaborations between FQ-treated persons who have developed long-term neuropsychiatric (NP) toxicity, pharmacovigilance experts, and basic scientists. That is the basis for this paper.
I, and a few other floxies, developed, conducted, and analyzed a web-based survey of persons who experienced possible FQ-associated toxicity and provided that data to Dr. Bennett and his team to use as supportive data for this report.
I also want to thank our very own Alan Redd PhD who assisted with this paper and is listed as one of the co-authors.
Dr. Raja Fayad, a co-author, a brilliant researcher, and also an important FQ community research advocate was working on this paper with Dr. Bennett, at the time of his untimely and tragic demise. His brilliance and research advocacy will be greatly missed.
Dr. Bennett was one of three major academic researchers that saw the true impact of FQ toxicity and agreed to work with us on behalf of the FQ community. We have been working with him for many years now. He has been, and continues to be, a strong research advocate, speaking on the cautions and safe use of pharmaceuticals in our society.
You can access Dr. Bennett’s paper for viewing here: “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.” *
Stayed tuned to My Quin story for timely updates on our interactions with the FDA, Dr. Bennett and the Citizen Petition, and community related research.
* Copyright 2016, The Journal of Community and Supportive Oncology, All rights reserved. For permission to reuse any of this content visit